• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the Editor: Comment on: "BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma".

作者信息

Yu Shi-Tong, Lei Shang-Tong

机构信息

Department of General Surgery, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.

出版信息

Ann Surg Oncol. 2024 Jun;31(6):3737-3738. doi: 10.1245/s10434-024-15225-9. Epub 2024 Mar 21.

DOI:10.1245/s10434-024-15225-9
PMID:38512604
Abstract
摘要

相似文献

1
Letter to the Editor: Comment on: "BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma".致编辑的信：对“BRAF V600E突变与甲状腺乳头状癌较差临床预后无关”的评论
Ann Surg Oncol. 2024 Jun;31(6):3737-3738. doi: 10.1245/s10434-024-15225-9. Epub 2024 Mar 21.
2
ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?ASO作者反思：BRAF V600E突变与甲状腺乳头状癌较差的临床预后相关吗？
Ann Surg Oncol. 2024 Jun;31(6):3974-3975. doi: 10.1245/s10434-024-15058-6. Epub 2024 Feb 16.
3
Evaluation of the expression levels of BRAF mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.应用超敏突变检测法评估甲状腺癌原发灶中 BRAF mRNA 的表达水平。
BMC Cancer. 2020 May 1;20(1):368. doi: 10.1186/s12885-020-06862-w.
4
[The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].[BRAF V600E突变与影响甲状腺乳头状癌发生及预后因素的相关性]
Zhonghua Bing Li Xue Za Zhi. 2019 Apr 8;48(4):288-292. doi: 10.3760/cma.j.issn.0529-5807.2019.04.005.
5
Incidence of V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience.甲状腺乳头状癌患者中V600E突变的发生率：单机构经验
J Int Med Res. 2019 Nov;47(11):5560-5572. doi: 10.1177/0300060519873481. Epub 2019 Sep 18.
6
The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.BRAF V600E突变作为甲状腺乳头状癌预后分层潜在标志物的作用：一项长期随访研究
Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169. Epub 2014 Mar 28.
7
BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.BRAF V600E 突变与致癌突变共存与甲状腺乳头状癌侵袭性临床病理特征和不良预后相关。
Asian J Surg. 2024 Jan;47(1):413-419. doi: 10.1016/j.asjsur.2023.09.049. Epub 2023 Sep 24.
8
An Animal Model Further Uncovers the Role of Mutant Braf during Papillary Thyroid Cancer Development.一种动物模型进一步揭示了突变型 Braf 在甲状腺乳头状癌发展过程中的作用。
Am J Pathol. 2020 Mar;190(3):702-710. doi: 10.1016/j.ajpath.2019.11.006. Epub 2020 Jan 14.
9
BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.BRAF V600E 突变与甲状腺乳头状癌的临床预后不良无关。
Ann Surg Oncol. 2024 May;31(5):3495-3501. doi: 10.1245/s10434-024-14935-4. Epub 2024 Feb 1.
10
Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.识别甲状腺乳头状癌中的 LMO7-BRAF 融合基因。
Thyroid. 2018 Jun;28(6):748-754. doi: 10.1089/thy.2017.0258. Epub 2018 May 16.

本文引用的文献

1
ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?ASO作者反思：BRAF V600E突变与甲状腺乳头状癌较差的临床预后相关吗？
Ann Surg Oncol. 2024 Jun;31(6):3974-3975. doi: 10.1245/s10434-024-15058-6. Epub 2024 Feb 16.
2
Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.局部晚期或远处转移性分化型甲状腺癌患者的融合癌基因。
J Clin Endocrinol Metab. 2024 Jan 18;109(2):505-515. doi: 10.1210/clinem/dgad500.
3
The lymph node yield in the initial lateral neck dissection predicts recurrence in the lateral neck of papillary thyroid carcinoma: a revision surgery cohort study.
初始侧颈部淋巴结清扫术的淋巴结检出量可预测甲状腺乳头状癌侧颈部复发：一项修正手术队列研究。
Int J Surg. 2023 May 1;109(5):1264-1270. doi: 10.1097/JS9.0000000000000316.
4
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
5
Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.融合基因与儿童甲状腺癌的转移能力增加和疾病持续存在相关。
J Clin Oncol. 2022 Apr 1;40(10):1081-1090. doi: 10.1200/JCO.21.01861. Epub 2022 Jan 11.
6
Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.初始中央颈部清扫术（CND）中的淋巴结检出量与甲状腺乳头状癌复发风险的相关性：一项再次手术 CND 队列研究。
Oral Oncol. 2021 Dec;123:105567. doi: 10.1016/j.oraloncology.2021.105567. Epub 2021 Oct 25.
7
The Genetic Duet of V600E and Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer.V600E 和启动子突变的遗传二重奏可准确预测复发性甲状腺乳头状癌对放射性碘摄取能力的丧失。
J Nucl Med. 2020 Feb;61(2):177-182. doi: 10.2967/jnumed.119.227652. Epub 2019 Aug 2.
8
Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer.对于年龄小于 45 岁的甲状腺乳头状癌患者，淋巴结转移的存在和数量与生存受损有关。
J Clin Oncol. 2015 Jul 20;33(21):2370-5. doi: 10.1200/JCO.2014.59.8391. Epub 2015 Jun 15.